St. Louis, MO
Home ► Personal Injury Lawsuit – All of your Legal Questions Answered ► Do I Qualify to Participate in a Bad Drug Lawsuit? ► Belviq Lawsuit | Belviq Recall | Belviq Lawyer | Belviq Cancer Risk
The popular weight-loss supplement Belviq has been linked to a number of dangerous side effects, including increased cancer risks. The FDA recently recalled Belviq due to the increased cancer risks. If you or a loved one was prescribed Belviq and developed cancer, you should contact a Belviq cancer lawyer right away. You may qualify to participate in a Belviq cancer lawsuit. Contact TorHoerman Law for a free no-obligation Belviq lawsuit consultation. Speak with a Belviq lawyer from TorHoerman Law and discuss your legal options.
The Food and Drug Administration (FDA) announced that Belviq (lorcaserin), a popular weight-loss drug, would be pulled from the United States market as of February 2020. The announcement came following research findings that tied Belviq and Belviq XR to increased cancer rates. Researchers have been studying Belviq’s safety for five years and found increased reported rates of cancer in people who took the medication. The FDA recommended that people who use Belviq for weight loss immediately stop taking the medicine.
Belviq (lorcaserin) is a popular prescription weight-loss drug. The drug is sold and produced by Eisai Inc., a Tokyo-based drugmaker. Belviq was initially approved by the FDA in 2012 for U.S. markets.
Belviq alters the brain’s chemical signals responsible for appetite and increases feelings of fullness to help patients lose weight. The drug is used as a combined treatment with diet and exercise to help adults who are overweight, obese, or suffering weight-related medical problems. Belviq is sometimes prescribed to treat obesity linked to diabetes, high blood pressure, and high cholesterol, but it does not treat underlying health conditions.
Belviq (lorcaserin) is available in two separate forms. Belviq is a 10 mg tablet prescribed to be taken twice a day. Belvin XR is an extended-release form of lorcaserin prescribed as one daily dose.
The Food and Drug Administration requested that Eisai Inc. withdraw Belviq from U.S. markets citing concerns over the drug’s ties to cancer. Since Belviq was approved in 2012, researchers have been studying the medication’s safety. The FDA originally required that the drug manufacturer conduct a double-blind, randomized, placebo-controlled clinical trial that tested for risks of heart-related health problems.
The researchers analyzed approximately 12,000 participants, some of who were given Belviq while some took a placebo. Researchers did not discover subsequent heart problems tied to Belviq, but they did find that patients taking the drug had a higher cancer diagnosis rate than those who took a placebo.
FDA researchers discovered increased rates of cancer in patients prescribed Belviq. About 7.7 percent of patients who took Belviq had a cancer diagnosis compared to 7.1 percent who received a placebo. Over the course of the trial, 662 Belviq patients were diagnosed with 520 primary cancers while the placebo group had 423 patients diagnosed with 470 cancers. The FDA also reported that the longer a patient was on Belviq, the greater the increased risk of developing cancer.
Early studies performed on rats also hinted that Belviq might cause cancer. Prior to the drug’s approval in 2012, manufacturer testing linked Belviq to an increased rate of cancerous tumors in rats. The FDA was concerned with the findings, but the risks were not deemed significant enough to pull Belviq from markets. The FDA has reversed its stance following the 2020 research that showed definitive evidence linking Belviq and cancer.
The FDA requested the recall of Belviq and Belviq XR because of increased rates of cancers tied to the drug. The agency reported several different types of cancers including:
Studies reveal Belviq causes an increased risk of Pancreatic cancer.
Studies reveal Belviq causes an increased risk of colorectal cancer.
Studies reveal Belviq causes an increased risk of lung cancer.
Researchers are studying the possible Belviq links to increased risks of other cancers, including breast cancer and brain cancer.
The FDA announced in January that clinical trial results tied Belviq and Belviq XR to a possible increased risk of cancer. The agency said that the drug’s cancer risks were significant enough to call for the drug to be removed from the U.S. market. The agency notes that they cannot conclude that Belviq and Belviq XR contribute to the cancer risks, and the cause of developed cancers is still uncertain.
However, the agency noted that risks of the medicine outweigh its benefits and recommend people using Belviq for weight loss stop taking the drug immediately.
The FDA recommended that people taking Belviq or Belviq XR immediately stop taking the drug following research findings tying the medication to increased cancer risks. The medication also presents numerous other risks and side effects. It’s important to note that the drug was only approved for people who are obese (with a body-mass index of 30 or more) or overweight (with a BMI between 27 and 30) and have high blood pressure, high cholesterol, or diabetes.
Belviq side effects include:
Patients with diabetes who take lorcaserin can also experience back pain, coughing, and hypoglycemia as a result of taking the drug.
Lorcaserin can also cause heart valve issues and slowed heartbeat.
The Drug Enforcement Agency classifies the medication as a Schedule IV controlled substance citing risks of dependence; people who take more than prescribed might experience hallucinations, slowed thinking, and euphoria.
Belviq can also adversely interact with other medications.
The European Medicines Agency also rejected the drug over safety concerns in 2012.
The U.S Food and Drug Administration requested the weight-loss drug Belviq to be pulled from U.S. markets in February after safety clinical trials tied the medication to increased rates of cancer. Eisai Inc., the Tokyo-based manufacturer of the drug, submitted voluntary requests to withdraw the drug from the market.
FDA officials said that Belviq’s cancer risks are significant enough for the agency to call for the removal of the drug. Since the approval of the drug, researchers have been conducting a five-year study to analyze the medication’s safety profile. Researchers found that approximately 7.7 percent of patients who took Belviq received a cancer diagnosis, compared to 7.1 percent of patients who took a placebo.
The FDA has made these recommendations for patients Belviq patients and healthcare professionals:
FDA officials recommended that people taking Belviq stop immediately. Patients should talk to a health care provider to find alternative weight-loss drugs and weight management programs. Belviq should be disposed of at a drug take-back location, or in household trash using the following steps:
The agency is not recommending special cancer screening for patients who took Belviq. Patients should still schedule regular recommended cancer screenings. Patients should reach out to their healthcare provider with any questions.
The FDA states that healthcare providers should stop prescribing and dispensing Belviq and Belviq XR to their patients. Providers should contact any patients who currently take the drug to inform them of results from the clinical trials and ask them to stop taking the medication. Work with patients to find safer medications and weight-loss strategies.
To help the FDA track safety issues with Belviq and other medications, the agency encourages health professionals and patients to report side effects and adverse reactions to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program.
Information can be submitted through:
Patients who took Belviq or Belviq XR and developed cancer or other adverse side effects might be eligible for a Belviq lawsuit. If you took Belviq or Belviq XR and were diagnosed with pancreatic, colorectal, lung cancer, or other cancers, a Belviq cancer lawyer from TorHoerman Law will work to seek the following damages for you:
The first step to filing a Belviq lawsuit is hiring a personal injury lawyer to act as your Belviq cancer lawyer. Your state’s statute of limitations allows only a certain window of time for you to take legal action after suffering an injury, so it is important to find a Belviq cancer lawyer and file your Belviq lawsuit as soon as possible.
In the unfortunate event that your loved one died as a result of cancer from Belviq, you might need to consult a wrongful death attorney.
Your Belviq cancer lawyer will stress this, but another important first step is to mitigate injuries and future costs by seeking medical treatment right away and following your doctor’s orders.
Filing a Belviq cancer lawsuit requires the same steps as any other bad drug lawsuit. Familiarize yourself with steps of the civil litigation process before you begin.
Your Belviq cancer lawyer will help identify liability – who is liable for you or your loved one’s diagnosis.
It’s important to start gathering evidence as soon as possible to support your claim against the manufacturer or liable party. This evidence includes medical bills and proof of damages, loss of wages, and documented physical and emotional suffering. This will help prove the total cost of losses endured resulting from your diagnosis. In many bad drug lawsuits, the injured party can file for both compensatory damages and punitive damages.
After calculating your total damages, you will determine how much compensation you desire from your Belviq lawsuit to cover your total costs.
Your Belviq cancer lawyer will fight to maximize your compensation, either by settling with the liable party outside of court or moving along into a Belviq lawsuit trial.
Hiring the best Belviq cancer lawyer is crucial in receiving proper compensation for you or your loved one’s suffering. At TorHoerman Law, our law firm will work with you to navigate the legal system and help you successfully file your Belviq cancer lawsuit. We offer free, no-obligation case evaluations and consultations for all potential Belviq cancer lawsuit clients.
TorHoerman Law operates on a contingency fee basis – meaning we don’t expect payment unless we win. So, we are as dedicated as our clients to get the best potential outcome from their Belviq lawsuit.
Contact TorHoerman Law today to learn about your potential Belviq lawsuit and legal options.
TorHoerman Law – Your Belviq Cancer Law Firm
Adam Feuerstein, et al. “Weight-Loss Drug to Be Pulled from Market over Concerns of Cancer Risk.” STAT, 14 Feb. 2020, www.statnews.com/2020/02/13/weight-loss-drug-to-be-pulled-from-market-after-fda-expresses-concerns-on-cancer-risk/?utm_campaign=pharmalittle&utm_source=hs_email&utm_medium=email&utm_content=83374306&_hsenc=p2ANqtz--bny2xWbvORwXm9561LyfZbPHeSSv8e0glWu68iawHDrGfISgwYqL3uQJztwX8hVBbhpFCaWLDuLQ1eVZeowpJrpEQqQ&_hsmi=83374306.
Center for Drug Evaluation and Research. “FDA Requests Withdrawal of Belviq, Belviq XR.” U.S. Food and Drug Administration, FDA, www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market.
FDA MedWatch - Belviq, Belviq XR (Lorcaserin) by Eisai: Drug Safety Communication - FDA Requests Withdrawal of Weight-Loss Drug, s2027422842.t.en25.com/e/es s=2027422842&e=302011&elqTrackId=376c7bc788024cd5a73d955f2e3dcbdc&elq=161695e97ec047449bf573f85b4cf908&elqaid=11242&elqat=1.
The Washington Post. “Weight-Loss Drug Belviq Pulled off U.S. Market Because of Cancer Concerns.” The Washington Post, WP Company, 14 Feb. 2020, www.washingtonpost.com/business/economy/weight-loss-drug-belviq-pulled-off-us-market-because-of-cancer-concerns/2020/02/14/9ccb2dd6-4f2b-11ea-b721-9f4cdc90bc1c_story.html.
“Weight-Loss Pill Belviq Is NOT Recommend - Consumer Reports.” Weight-Loss Pill Belviq Is NOT Recommend - Consumer Reports, www.consumerreports.org/cro/news/2013/06/weight-loss-pill-belviq-is-now-available-but-we-say-skip-it/index.htm.
Last Modified: March 2nd, 2020 @ 09:36 am
© 2019 TorHoerman Law LLC.
The contents of this webpage have been prepared by TorHoerman Law, LLC for informational purposes only. None of this information is intended as either legal or medical advice or opinions. No attorney/client relationship is established with use of this website. Sending or receiving information through this site, posting to our blogs/news site does not establish an attorney/client relationship. An attorney/client relationship with TorHoerman Law is established only by an express and written agreement by TorHoerman Law to represent you. Our attorneys make a case-by-case assessment of any claims and results may vary depending on the facts concerning any case. The attorneys at TorHoerman Law are licensed to practice in Illinois, Missouri, and California. In some circumstances, cases may be sent to other qualified lawyers. In those circumstances, TorHoerman Law maintains joint responsibility.